GLENMARK - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.5
| Stock Code | GLENMARK | Market Cap | 67,906 Cr. | Current Price | 2,406 ₹ | High / Low | 2,474 ₹ |
| Stock P/E | 45.8 | Book Value | 848 ₹ | Dividend Yield | 0.10 % | ROCE | 9.72 % |
| ROE | 7.35 % | Face Value | 1.00 ₹ | DMA 50 | 2,181 ₹ | DMA 200 | 1,988 ₹ |
| Chg in FII Hold | 1.15 % | Chg in DII Hold | -0.81 % | PAT Qtr | 426 Cr. | PAT Prev Qtr | 193 Cr. |
| RSI | 70.5 | MACD | 67.6 | Volume | 8,13,703 | Avg Vol 1Wk | 8,89,922 |
| Low price | 1,340 ₹ | High price | 2,474 ₹ | PEG Ratio | 22.9 | Debt to equity | 0.02 |
| 52w Index | 94.0 % | Qtr Profit Var | 3.00 % | EPS | 0.74 ₹ | Industry PE | 30.1 |
📈 Chart & Trend: GLENMARK is trading above both its 50 DMA (2,181 ₹) and 200 DMA (1,988 ₹), confirming strong bullish momentum. RSI at 70.5 indicates overbought conditions, while MACD at 67.6 remains strongly positive. Bollinger Bands show price near the upper band, suggesting short-term resistance and potential profit booking.
🔎 Momentum Signals: Current volume (8.13 lakh) is slightly below the 1-week average (8.89 lakh), hinting at mild cooling. Momentum remains strong but stretched, with risk of consolidation.
🎯 Entry Zone: 2,150–2,200 ₹ (support near 50 DMA)
🚪 Exit Zone: 2,450–2,470 ₹ (resistance near 52-week high)
📊 Trend Status: Trending upward but overbought; consolidation likely.
Positive
- Strong quarterly PAT growth (426 Cr. vs 193 Cr.).
- FII holdings increased (+1.15%), showing foreign investor confidence.
- Low debt-to-equity (0.02) ensures financial stability.
- Trading near 52-week high (94% index), reflecting strong momentum.
Limitation
- High P/E (45.8) compared to industry average (30.1), indicating overvaluation.
- Weak ROCE (9.72%) and ROE (7.35%) highlight poor capital efficiency.
- PEG ratio (22.9) signals expensive growth expectations.
- DII holdings decreased (-0.81%), showing reduced domestic support.
Company Negative News
- No major negative news reported; valuation and efficiency concerns remain key risks.
Company Positive News
- Strong quarterly earnings momentum with PAT growth.
- Foreign institutional investors increasing stake.
Industry
- Industry P/E at 30.1 reflects moderate valuations across pharma sector.
- Sector supported by demand for generics and specialty drugs.
Conclusion
GLENMARK is in a strong uptrend but overbought, with limited upside near its 52-week high. Entry near 2,150–2,200 ₹ offers better risk-reward, while profit booking is advised near 2,450–2,470 ₹. Short-term consolidation is likely, while long-term outlook depends on improving ROE/ROCE and sustaining earnings growth.
This modular HTML report is tuned for your workflow. Would you like me to extend this into a swing vs. investment horizon overlay so you can see how GLENMARK’s momentum differs across short-term and long-term strategies?